BiCKI

**BiCKI** is OSE Immunotherapeutics' **Bispecific ChecKpoint Inhibitor** platform in immuno-oncology rather than a single fully specified clinical drug asset. The platform is described as a **bispecific fusion protein** backbone built around an **anti-PD-1** component combined with an additional immunotherapy effector module to enhance antitumor activity. The most advanced named candidate identified from the provided context is **BiCKI-IL-7**, an anti-PD-1 x IL-7 fusion protein intended for the treatment of **neoplasms** and reported to be in **preclinical development**. Because the query term refers to the platform name rather than one unique molecular entity, annotations below reflect BiCKI as a nonspecific platform-level drug concept.

Other names

Bispecific ChecKpoint Inhibitor